HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for ...

The Food and Drug Administration (FDA) has granted Fast Track designation to nadunolimab for the treatment of patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) with ...

Ductal carcinoma in situ (DCIS) is a heterogeneous group of diseases that differ in biology and clinical behavior. Until 1980, DCIS represented less than 1% of all breast cancer cases. With the ...

AbstractActivating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment, ...

Ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, affects more than 60,000 U.S. women each year. (iStock) ...

About PDAC Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer deaths, with a five-year survival rate of approximately 10% - the lowest among all solid tumors.

Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) and Phase 1 study in pancreatic ductal adenocarcinoma (PDAC), with earlier ...

Development of methods to accurately detect the expression and activity of protein targets inside live cells is of great significance for disease diagnostics and drug development. Inductively coupled ...

(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma rapid oral abstract session and a presentation by Dr. Xinan Sheng discussing results from a phase 1b/2 study assessing ...

Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall survival (mOS) of between 8 and 11 months. With the use of modern chemotherapy ...